AstraZeneca Sells Heart Drug Rights to Recordati

23.05.2017 - AstraZeneca has sold European rights for its Seloken/Seloken ZOK and Logimax cardiovascular drugs to Italy’s Recordati for $300 million. The medicines, which are used to treat...